StemCell InstituteTSE:7096 +0.92%69 Gross Margin % is 60.22% as of Mar. 2026, which is 6% below its 10-year median of 63.88. GuruFocus rates TSE:7096 with a GF Score™ of 69/100 and a GF Value™ of 円1,813.29 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 732 Biotechnology companies, StemCell Institute ranks worse than 50.14% on this metric.
The historical rank and industry rank for StemCell Institute's Gross Margin % or its related term are showing as below:
TSE:7096'
s Gross Margin % Range Over the Past 10 Years
Min: 60.9 Med: 63.88 Max: 67.56
Current: 60.9
During the past 9 years, the highestGross Margin % of StemCell Institute was 67.56%. The lowest was 60.90%. And the median was 63.88%.
TSE:7096's Gross Margin % is ranked worse than 50.14% of 732
companies
in the Biotechnology industry
Industry Median: 60.905
vs TSE:7096: 60.90
StemCell Institute had a gross margin of 60.22% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for StemCell Institute was -1.00% per year.
StemCell Institute (TSE:7096) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
StemCell Institute had a gross margin of 60.22% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
StemCell Institute Gross Margin % Related Terms
StemCell Institute Gross Margin % Historical Data
* Premium members only.
The historical data trend for StemCell Institute's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7096 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, StemCell Institute's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCell Institute Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCell Institute's Gross Margin % distribution charts can be found below:
* The bar in red indicates where StemCell Institute's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
StemCell Institute (TSE:7096) has a Gross Margin % of 60.22% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on StemCell Institute and its competitors. This is near median its historical median of 63.88. Over the past decade, StemCell Institute's Gross Margin % has ranged from 60.90 to 67.56. According to the industry distribution chart, StemCell Institute ranks #367 out of 732 companies in the Biotechnology industry, placing it in the top 50.1%.
Is StemCell Institute's Gross Margin % too high?
StemCell Institute's current Gross Margin % of 60.22% is near median its 10-year median of 63.88. Over the past 10 years, this metric has ranged from a low of 60.90 to a high of 67.56. The Biotechnology industry median Gross Margin % is 60.91. StemCell Institute's value of 60.22% is 1.1% below this industry median. Based on the distribution chart, StemCell Institute ranks #367 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, StemCell Institute has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCell Institute ranks #367 out of 732 companies for Gross Margin %. This places StemCell Institute in the lower half of its industry. The industry median Gross Margin % is 60.91. StemCell Institute's value of 60.22% is 1.1% below this benchmark. Historically, StemCell Institute's own Gross Margin % has ranged from 60.90 to 67.56 over the past decade. While the company's 10-year median is 63.88 vs. the industry median of 60.91, StemCell Institute has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. StemCell Institute's current Gross Margin % of 60.22% is 1.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on StemCell Institute and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. StemCell Institute's current Gross Margin % is 60.22%, which is near median its own 10-year median of 63.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,813.29, compared to a current price of 円768.00 — trading 57.6% below its estimated fair value. The current Gross Margin % is 60.22%, which is near median its 10-year median of 63.88 and 1.1% below the Biotechnology industry median of 60.91. StemCell Institute's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current Gross Margin % is 60.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is StemCell Institute (TSE:7096) Overvalued in 2026?
Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued.
The current stock price of 円768.00 is trading 57.6% below its estimated GF Value™ of 円1,813.29.
GuruFocus considers StemCell Institute to be Possible Value Trap.
Key valuation signals for TSE:7096:
Gross Margin %: 60.22% (near median its 10-year median of 63.88)
GF Value™: 円1,813.29 vs. price of 円768.00 (57.6% below fair value)
Industry Position: 1.1% below the Biotechnology median (#367 of 732)
No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
69GF Score
Get the complete analysis for TSE:7096
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7096 has been successfully added to your 
